Just a month out from being bought by French giant bioMérieux, BioFire Diagnostics took its FilmArray diagnostic system's new gastrointestinal option to the FDA for clearance, which the newly united ...
BioFire Diagnostics won 510(k) clearance for its gastrointestinal panel for infectious diarrhea, following in the footsteps of the company's acquisition by French diagnostic giant bioMérieux.
SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., recently announced that it has commenced clinical and analytical studies to evaluate the company’s FilmArray Gastrointestinal (GI) Panel, ...
Exciting news! The BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel that you know and love now offers a new feature called C. difficile Select! This feature allows users running the BIOFIRE GI Panel ...
Syndromic molecular panels have revolutionized clinical diagnostics—but what happens when post-market performance drifts? Our latest preprint on medRxiv dives into the molecular mechanisms driving the ...
MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results